Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. | CardiolRx - (LANCER) | Cardiovascular disease (CVD) in COVID-19 pateints | Phase 2/3 | Oral | COVID-19 | |
| CARGO Therapeutics Inc. | Firicabtagene autoleucel (firi-cel) (CRG-022) | R/R LBCL - post CD19 Car T | Phase 2 | Trial Completed | Intravenous infusion | Oncology |
| Cartesian Therapeutics Inc. | Descartes-08 | Myositis | Phase 2 | Trial Planned | Intravenous | Immunology |
| Cartesian Therapeutics Inc. | SEL-212 - (DISSOLVE) | Chronic Refractory Gout | BLA Filing | Trial Planned | Intravenous | N/A |
| Cartesian Therapeutics Inc. | Descartes-08 - (pediatric basket study) | Neurology and rheumatology autoimmune indications, juvenile dermatomyositis (JDM) | Phase 2 | Trial Planned | Intravenous | Immunology |
| Cartesian Therapeutics Inc. | Descartes-08 - (AURORA) | Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune Diseases | Phase 3 | Trial Planned | Intravenous | Immunology |
| Cartesian Therapeutics Inc. | SEL-212 (COMPARE) - Head to head trial vs Krystexxa | Tophaceous gout | Phase 2 | Trial Discontinued | Intravenous | N/A |
| Cartesian Therapeutics Inc. | Descartes-08 - (open-label) | Systematic lupus erythematosus (SLE) | Phase 2 | Data Released | Intravenous | Immunology |
